outperform
reason report
downgrad mp neg shine data pt
bottom line downgrad ifrx share market perform
sinc although indic anca-associ vascul
aav may provid better shot goal inhibit
believ investor question mechan stock
dead money data studi prove mechan
worthwhil ifrx expect open-label extens studi data
avail come week along addit analys
shine unfortun see reason addit
analys trial extens studi look suffici better
manag alreadi see reason advanc lower pt
manag believ cash provid adequ
runway gener data studi three phase studi
start pyoderma gangrenosum pg aav
us aav eu could read
time frame respect base clinicaltri gov meanwhil
op report advoc data avacopan aav
silver line could safe lower dose-
depend manner henc diseas may directli
link elev could present better opportun success
unfortun less hope posit data pg anoth
skin diseas avacopan oral drug investor may limit
posit read-through advoc sinc administ
spoke manag shock result sinc
overal blind respons rate mid rang
assum placebo respons high end
hs trial would impli respect efficaci
believ high placebo rate rais question trial conduct
manag note site train audit suggest
key contributor disappoint compani still
search reason unsur specul intraven iv
administr may caus placebo rate higher
studi hs howev note placebo rate
bermekimab nr even lower usual week
versu drug inexplic high placebo rate remind us
advers outcom op march suffer
error contract research organ cro mistakenli
score phase trial howev overal low respons
rate lack dose respons fact share
regain valu lost event provid littl
consol even case ifrx continu next page
rate termin growth rate
convert impli market cap
eur usd use month fx
net debt total capit
year price history/av daili volume mil ifrx
compani inform svb leerink llc research
revenu eur revenu ep conform ifr standard financi provid part ipo
pleas refer page import disclosur price chart analyst certif
lower pt elimin hs opportun
opex chang junctur think logic remov
hs opportun probabl us eu
although earlier develop ascrib probabl
anca-associ vascul aav oppti given posit preced
ccxi op avacopan data thu far hs effort wind
subsequ indic aav pg like requir smaller
trial trim opex project near-term
latter year pend futur updat updat model pg
inflarx clinical-stag biopharmaceut compani focus appli proprietari
drug discoveri platform gener first-in-class inhibitor halt excess
inflamm caus complement factor innat immun prevail
pro-inflammatori mediat whose dysregul result progress wide varieti
autoimmun diseas inhibit attract yet elus target drug
develop repres opportun restrain extrem inflamm
preserv necessari anti-infect action inhibitor alexion
soliri eculizumab dull edg innat immun prevent
immun respons howev think inflarx overcom hurdl first-in class anti-
mab inflarx intend develop proprietari antibodi address
wide array inflammatory-medi diseas signific unmet medic need includ
anca-associ vascul aav pyoderma gangrenosum pg
model incorpor anca-associ vascul aav program exclud
program believ inflarx share best valu via dcf analysi use discount
rate termin growth rate convert impli market cap eur usd use
fx averag yield pt
pre-commerci stage compani risk valuat includ clinic trial outcom delay
clinic develop regulatori risk prior approv reimburs risk post-approv
also sinc first-in-class therapi unforeseen complic risk may emerg
financi perspect clinic develop requir signific invest could
necessit financ road
equival
chang cash eur
purchas secur current invest
proce issuanc preferred/common share
transact cost issuanc stock
net borrow debt form loan
